Mirvetuximab Soravtansine Combination Improves Responses in Platinum-Agnostic Ovarian Cancer
Lucy Gilbert, MD, MSc, discusses the findings from a phase 1b trial in which mirvetuximab soravtansine was combined with bevacizumab in recurrent, high-grade epithelial ovarian cancer regardless of platinum sensitivity.
Lucy Gilbert, MD, MSc, professor, Department of Obstetrics & Gynecology and the Department of Oncology, McGill University and director of Gynecologic Oncology and Women’s Health Research Unite, McGill University Health Centre, discusses the findings from a phase 1b trial in which mirvetuximab soravtansine was combined with bevacizumab (Avastin) in recurrent, high-grade epithelial ovarian cancer regardless of platinum sensitivity.
The overall response rate (ORR) was 47%, but in patients with high folate receptor alpha (FRα) expression, the ORR was 64%, which is a very encouraging finding. When looking at the subgroup of patients with high FRα-expression, the ORR is 59% among those with platinum-resistant disease, which is almost double what has been seen with other agents in this setting, says Gilbert. In the platinum-sensitive subset, the ORR is also encouraging at 69%.
Data for progression-free survival and duration of response were still immature, but almost half the patients remained on treatment after a median follow-up of 8.5 months.
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
